Cytokeratin 3 Antibody (Mouse mAb) [N24P21]

CatNo: F2198

Application: Reactivity: Human

Lane 1: 293T (empty vector transfected), Lane 2: 293T (Cytokeratin full length expression vector transfected)

当該製品は品切れ状态で、メールアドレスをご教示いただければ、お客様に返信いたします。

代表番号: 045-509-1970|電子メール：sales@selleck.co.jp

使用情報

Dilution
IHC1:800

Application
IHC

Source
Mouse Monoclonal Antibody

Reactivity
Human

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
64 kDa 65 kDa
^*なぜ予測分子量と実際の分子量が異なるのか？下記の原因により、実際の分子量が予測と異なる：タンパク質の翻訳後修飾（リン酸化/糖鎖付加），スプライシングバリアント，イソフォーム，相対的な電荷，ポリマー。

ポジティブコントロール	Human squamous papilloma of cornea tissue
ネガティブコントロール

プロトコール

IHC
Experimental Protocol： Deparaffinization/Rehydration 1. Deparaffinize/hydrate sections: 2. Incubate sections in three washes of xylene for 5 min each. 3. Incubate sections in two washes of 100% ethanol for 10 min each. 4. Incubate sections in two washes of 95% ethanol for 10 min each. 5. Wash sections two times in dH2O for 5 min each. 6.Antigen retrieval: For Citrate: Heat slides in a microwave submersed in 1X citrate unmasking solution until boiling is initiated; continue with 10 min at a sub-boiling temperature (95°-98°C). Cool slides on bench top for 30 min. Staining 1. Wash sections in dH2O three times for 5 min each. 2. Incubate sections in 3% hydrogen peroxide for 10 min. 3. Wash sections in dH2O two times for 5 min each. 4. Wash sections in wash buffer for 5 min. 5. Block each section with 100–400 µl of blocking solution for 1 hr at room temperature. 6. Remove blocking solution and add 100–400 µl primary antibody diluent in to each section. Incubate overnight at 4°C. 7. Remove antibody solution and wash sections with wash buffer three times for 5 min each. 8. Cover section with 1–3 drops HRPas needed. Incubate in a humidified chamber for 30 min at room temperature. 9. Wash sections three times with wash buffer for 5 min each. 10. Add DAB Chromogen Concentrate to DAB Diluent and mix well before use. 11. Apply 100–400 µl DAB to each section and monitor closely. 1–10 min generally provides an acceptable staining intensity. 12. Immerse slides in dH2O. 13. If desired, counterstain sections with hematoxylin. 14. Wash sections in dH2O two times for 5 min each. 15. Dehydrate sections: Incubate sections in 95% ethanol two times for 10 sec each; Repeat in 100% ethanol, incubating sections two times for 10 sec each; Repeat in xylene, incubating sections two times for 10 sec each. 16. Mount sections with coverslips and mounting medium.

IHC

Experimental Protocol：

Deparaffinization/Rehydration

1. Deparaffinize/hydrate sections:

2. Incubate sections in three washes of xylene for 5 min each.

3. Incubate sections in two washes of 100% ethanol for 10 min each.

4. Incubate sections in two washes of 95% ethanol for 10 min each.

5. Wash sections two times in dH2O for 5 min each.

6.Antigen retrieval: For Citrate: Heat slides in a microwave submersed in 1X citrate unmasking solution until boiling is initiated; continue with 10 min at a sub-boiling temperature (95°-98°C). Cool slides on bench top for 30 min.

Staining

1. Wash sections in dH2O three times for 5 min each.

2. Incubate sections in 3% hydrogen peroxide for 10 min.

3. Wash sections in dH2O two times for 5 min each.

4. Wash sections in wash buffer for 5 min.

5. Block each section with 100–400 µl of blocking solution for 1 hr at room temperature.

6. Remove blocking solution and add 100–400 µl primary antibody diluent in to each section. Incubate overnight at 4°C.

7. Remove antibody solution and wash sections with wash buffer three times for 5 min each.

8. Cover section with 1–3 drops HRPas needed. Incubate in a humidified chamber for 30 min at room temperature.

9. Wash sections three times with wash buffer for 5 min each.

10. Add DAB Chromogen Concentrate to DAB Diluent and mix well before use.

11. Apply 100–400 µl DAB to each section and monitor closely. 1–10 min generally provides an acceptable staining intensity.

12. Immerse slides in dH2O.

13. If desired, counterstain sections with hematoxylin.

14. Wash sections in dH2O two times for 5 min each.

15. Dehydrate sections: Incubate sections in 95% ethanol two times for 10 sec each; Repeat in 100% ethanol, incubating sections two times for 10 sec each; Repeat in xylene, incubating sections two times for 10 sec each.

16. Mount sections with coverslips and mounting medium.

Datasheet & SDS

生物学的記述

Specificity
Cytokeratin 3 Antibody (Mouse mAb) [N24P21] detects endogenous levels of total Cytokeratin 3/CK-3 protein.

タンパク質の局在
中間径フィラメント、ケラチン

Uniprot ID
P12035

Clone
N24P21

Synonym(s)
65 kDa cytokeratin, Cytokeratin-3, Keratin-3, Type-II keratin Kb3, CK-3, K3, KRT3

Background
Cytokeratin 3 (CK3, gene KRT3) is a type II intermediate filament keratin that forms an obligate heteropolymeric pair with the type I keratin K12 to build the cornea-specific cytoskeletal scaffold in differentiated corneal epithelium. This network supports mechanical resilience, barrier function, and the maintenance of corneal transparency by anchoring to desmosomal and hemidesmosomal complexes and integrating with the epithelial basement membrane. CK3/K12 filaments assemble into a dense cytoplasmic lattice whose organization depends on highly conserved helix boundary motifs and the glycine-rich tail domain—regions that mediate longitudinal filament assembly and lateral filament–filament packing. Even single amino-acid substitutions in these motifs can alter filament stability and increase susceptibility to mechanical shear. Within the corneal epithelium, this keratin pair defines the differentiated suprabasal compartment, marking the transition from limbal progenitors to mature central epithelial cells and coupling cytoskeletal status to junctional complexes that stabilize epithelial sheets and preserve an optically smooth surface. Pathogenic missense mutations in KRT3, particularly those affecting the helix boundary and glycine-loop regions, disrupt heteropolymer assembly with K12, generate keratin aggregates, and weaken the intermediate filament network. This results in epithelial cell fragility, microcyst formation, and recurrent erosions characteristic of Meesmann corneal dystrophy, demonstrating how precise CK3 structure–function relationships can translate into tissue-level mechanical failure. Genetic linkage and sequencing studies show that disease-associated KRT3 variants segregate with Meesmann corneal dystrophy in affected families and are absent from unaffected controls. Different mutations in either KRT3 or KRT12 can produce a similar phenotype by compromising the same filament-stabilizing motifs, reinforcing the concept that corneal epithelial integrity depends on balanced expression and correct pairing of this keratin duo. CK3 also functions as a corneal epithelial lineage marker. Immunohistochemical detection of CK3/CK12 defines cornea-type differentiation and reveals altered expression or mislocalization of these keratins in certain corneal dystrophies. Changes in CK3 levels after chemical injury or epithelial loss correlate with shedding and re-epithelialization dynamics, linking its expression pattern to injury responses and epithelial renewal.

Background

Cytokeratin 3 (CK3, gene KRT3) is a type II intermediate filament keratin that forms an obligate heteropolymeric pair with the type I keratin K12 to build the cornea-specific cytoskeletal scaffold in differentiated corneal epithelium. This network supports mechanical resilience, barrier function, and the maintenance of corneal transparency by anchoring to desmosomal and hemidesmosomal complexes and integrating with the epithelial basement membrane. CK3/K12 filaments assemble into a dense cytoplasmic lattice whose organization depends on highly conserved helix boundary motifs and the glycine-rich tail domain—regions that mediate longitudinal filament assembly and lateral filament–filament packing. Even single amino-acid substitutions in these motifs can alter filament stability and increase susceptibility to mechanical shear. Within the corneal epithelium, this keratin pair defines the differentiated suprabasal compartment, marking the transition from limbal progenitors to mature central epithelial cells and coupling cytoskeletal status to junctional complexes that stabilize epithelial sheets and preserve an optically smooth surface. Pathogenic missense mutations in KRT3, particularly those affecting the helix boundary and glycine-loop regions, disrupt heteropolymer assembly with K12, generate keratin aggregates, and weaken the intermediate filament network. This results in epithelial cell fragility, microcyst formation, and recurrent erosions characteristic of Meesmann corneal dystrophy, demonstrating how precise CK3 structure–function relationships can translate into tissue-level mechanical failure. Genetic linkage and sequencing studies show that disease-associated KRT3 variants segregate with Meesmann corneal dystrophy in affected families and are absent from unaffected controls. Different mutations in either KRT3 or KRT12 can produce a similar phenotype by compromising the same filament-stabilizing motifs, reinforcing the concept that corneal epithelial integrity depends on balanced expression and correct pairing of this keratin duo. CK3 also functions as a corneal epithelial lineage marker. Immunohistochemical detection of CK3/CK12 defines cornea-type differentiation and reveals altered expression or mislocalization of these keratins in certain corneal dystrophies. Changes in CK3 levels after chemical injury or epithelial loss correlate with shedding and re-epithelialization dynamics, linking its expression pattern to injury responses and epithelial renewal.

References
[1] Chen JL, et al. Mol Vis. 2015 Dec 31;21:1378-86. [2] Irvine AD, et al. Nat Genet. 1997 Jun;16(2):184-7.

PVDFメンブレン孔径参考表

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

* 大学・企業名 大学・企業名を記入してください

* 名前 名前を記入してください

* 電子メール 電子メール・アドレスを記入してください 有効なメールアドレスを入力してください

電話番号

* 内容 お問い合わせ内容をご入力ください

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%